Pharmaceutical Mini-academy - 02. Structuring In-licensed IPRs
Channel: MyTPAGlobal
Date: 17/06/2013

Lesson 1 to build an ideal pipeline: Should the MNE's in the pharmaceutical industry resort to in-license R&D from specialty shops and universities?

In the process of recreating their pipelines, pharmaceuticals are currently weighting their probabilities of R&D success against alternative options such as "cool stuff that doesn't kill you and you still make some money on". As such, we witness more in-license R&D agreements with "specialty shops" and universities. In the process of structuring in-licensed IPRs, MNE's seem to prefer the creation of centralized IP hubs or principle structures. During this webinar we will explore potential options that will soften the effect of high costs faced by centralized IPR hubs in low tax jurisdictions.

Web event host
- Ioanna Ninou, Associate, Transfer Pricing Associates

Guest speakers
- Steef Huibregtse, Founding Partner and CEO, Transfer Pricing Associates
- Yariv Ben-Dov, Founding Partner, Bar-Zvi & Ben-Dov

Did you miss another TPA Global web event? 
Download the (recorded) presentation at http://goo.gl/p8W4p